Clinical trial

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

NCT05186506

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Ensatinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention chemotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2022-01-01

PhasePHASE2

Conditions

ALK Fusion Protein Expressionunresolved

Adjuvant Therapyunresolved

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

EnsatinibDRUG

chemotherapyDRUG

Sponsors & collaborators

Sichuan Universitylead sponsor

Betta Pharmaceuticals Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05186506 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.